Evidence map›Paper›PMID 41217428›Full record

Trial reportAIDS (London, England)2026

Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.

Marissa R Diggs, Sarah M Chu, Kathleen V Fitch, Maxine Olefsky, Maya G Watanabe, Kristine M Erlandson, Alex B Lu, Gerald S Bloomfield, Judith S Currier, Adrian Curran and 14 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02344290. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02344290 phase3completed

Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE

Ran2015Enrolled7,769Registered outcomes37Posted comparisons40ConditionsCardiovascular Diseases, HIVArmsPitavastatin, Placebo
PMID 35235653PMID 32645161PMID 30928825PMID 37503623PMID 34794178PMID 34888395PMID 35147583PMID 34134131PMID 32645164PMID 32645162PMID 35165682PMID 35413022other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Marissa R DiggsMetabolism Unit, Massachusetts General Hospital, Harvard Medical School.
Sarah M ChuMetabolism Unit, Massachusetts General Hospital, Harvard Medical School.
Kathleen V FitchMetabolism Unit, Massachusetts General Hospital, Harvard Medical School.
Maxine OlefskyCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA.
Maya G WatanabeCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA.
Kristine M ErlandsonDivision of Infectious Diseases, Department of Medicine, University of Colorado - Anschutz Medical Campus, Aurora, CO.
Alex B LuMetabolism Unit, Massachusetts General Hospital, Harvard Medical School.
Gerald S BloomfieldDivision of Cardiology, Duke Global Health Institute and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Judith S CurrierDivision of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Adrian CurranInfectious Diseases Department, Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Allison Ross EckardDepartments of Pediatrics and Medicine, Divisions of Infectious Diseases, Medical University of South Carolina, Charleston, SC, USA.
Graham H R SmithMaple Leaf Medical Clinic, Toronto, Canada.
Craig A SponsellerKowa Pharmaceuticals America, Inc., Montgomery, AL.
Carl J FichtenbaumDivision of Infectious Diseases, University of Cincinnati College of Medicine.
Carlos D MalvestuttoDivision of Infectious Diseases, Ohio State University Medical Center, Columbus, OH.
Judith A AbergDivision of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY.
Borek FoldynaCardiovascular Imaging Research Center, Department of Radiology and Department of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jana TaronCardiovascular Imaging Research Center, Department of Radiology and Department of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Julia KaradyCardiovascular Imaging Research Center, Department of Radiology and Department of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Markella V ZanniMetabolism Unit, Massachusetts General Hospital, Harvard Medical School.
Pamela S DouglasDivision of Cardiology, Duke University School of Medicine, Durham NC, USA.
Heather J RibaudoCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA.
Michael T LuCardiovascular Imaging Research Center, Department of Radiology and Department of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Steven K GrinspoonMetabolism Unit, Massachusetts General Hospital, Harvard Medical School.

Funding

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2021 to 2025
$81.6M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2025
$6.0M
NHLBI NIH HHS U01 HL123336NHLBI NIH HHS U01 HL123339NIAID NIH HHS UM1 AI068634NIDDK NIH HHS P30 DK040561
6 · The paper itself

Abstract

backgroundThere is limited evidence concerning the relationship between cardiometabolic characteristics and health-related quality of life (HRQoL), and potential effects of statin therapy among people with HIV (PWH).

methodsThe Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) enrolled PWH aged 40-75 years on antiretroviral therapy (ART) with low-to-moderate ASCVD risk. Coronary computed tomography angiography assessed coronary plaque among a subset of participants in the REPRIEVE Mechanistic Substudy at baseline and 24 months. The Short Form-36-Item Health Survey Version 2 was collected at baseline, and physical (PCS) and mental (MCS) component summary scores were determined. We explored the relationship of PCS and MCS with cardiometabolic characteristics, coronary atherosclerosis, and assessed change in score by treatment group (pitavastatin vs. placebo).

resultsOf 733 participants, median age was 51 years, 84% were male, 34% were Black non-Hispanic, and median years diagnosed with HIV was 15. At baseline, for participants randomized to pitavastatin vs. placebo the median PCS was 54.5 (Q1, Q3: 46.9, 57.7) vs. 54.1 (47.5, 58.0), and the median MCS was 52.9 (44.1, 57.6) vs. 52.8 (44.0, 57.9). In fully adjusted analyses, older age, Black non-Hispanic race/ethnicity, ART regimen class, elevated BMI, and cigarette smoking were associated with lower PCS. No clear trends were apparent with MCS. Between baseline and month 24, declines in PCS and MCS were minimal with no apparent difference by treatment group.

conclusionsAmong this cohort of ART-treated PWH, baseline cardiometabolic risk factors were associated with worse self-reported physical HRQoL, with no apparent effect of statin therapy.

trial registrationREPRIEVE; NCT02344290; https://clinicaltrials.gov/study/NCT02344290.

Indexed as

AtherosclerosisHIV InfectionsQuality of LifeAdultAgedAnti-Retroviral AgentsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedAnti-Retroviral AgentsHydroxymethylglutaryl-CoA Reductase Inhibitorsatherosclerotic cardiovascular diseasecardiovascular diseasecoronary CT angiographyhealth-related quality of lifeHIVstatins

Identifiers

PMID41217428
PMCPMC12955952

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.